

**Table SII. Outcomes in Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and improvement in itch and Dermatology Life Quality Index (DLQI) scores at Weeks 4 and 12**

Parameter	Week 4				Week 12			
	PBO	ETN	IXE Q4W	IXE Q2W	PBO	ETN	IXE Q4W	IXE Q2W
PASI 75, %	1.7	9.9**	50.3***††	51.9***††	5.0	47.7**	81.0***††	88.5***††
PASI 90, %	0.3	2.2*	23.9***††	22.3***††	1.9	22.3**	62.6***††	69.3***††
PASI 100, %	0	0.4	6.0***††	8.2***††	0.3	6.4**	33.0***††	39.0***††
DLQI (0,1), %	7.2	18.8**	43.5***††	39.3***††	6.9	38.9**	61.9***††	64.4***††
Itch NRS, LS, mean (SE)	-0.4 (0.12)	-2.4 (0.08)**	-4.1 (0.08)***††	-4.2 (0.08)***††	-0.5 (0.12)	-3.8 (0.08)**	-4.9 (0.08)***††	-5.2 (0.08)***††
Itch NRS=0, %	2.8	7.3*	22.9***††	21.2***††	3.9	19.5**	40.2***††	43.1***††
Itch NRS ≤3, %	21.9.	50.0.**	76.1.**††	77.7.**††	27.4.	71.8**	85.5.**††	89.8.**††
DLQI Total Score, LS, mean (SE)	-1.9 (0.22)	-5.7 (0.16)**	-8.3 (0.16)***††	-8.5 (0.16)***††	-1.8 (0.24)	-7.8 (0.17)**	-9.5 (0.17)***††	-10.3 (0.17)***††
Symptoms and feelings, mean (SE)	-0.7 (0.06)	-1.6 (0.04)**	-2.5 (0.04)***††	-2.4 (0.04)***††	-0.5 (0.06)	-2.2 (0.04)**	-2.8 (0.05)***††	-3.0 (0.04)***††
Daily activities	-0.5 (0.06)	-1.2 (0.04)**	-1.9 (0.04)***††	-1.8 (0.04)***††	-0.4 (0.06)	-1.7 (0.04)**	-2.1 (0.04)***††	-2.3 (0.04)***††
Leisure	-0.5 (0.06)	-1.1 (0.04)**	-1.5 (0.04)***††	-1.5 (0.04)***††	-0.4 (0.06)	-1.4 (0.04)**	-1.7 (0.04)***††	-1.8 (0.04)***††
Work and school	-0.2 (0.03)	-0.5 (0.02)**	-0.6 (0.02)***††	-0.6 (0.02)***††	-0.2 (0.03)	-0.6 (0.02)**	-0.7 (0.02)**	-0.8 (0.02)***††
Personal relationships	-0.0 (0.05)	-0.8 (0.04)**	-1.2 (0.04)***††	-1.2 (0.04)***††	-0.1 (0.06)	-1.1 (0.04)**	-1.3 (0.04)***††	-1.4 (0.04)***††
Treatment	-0.1 (0.03)	-0.5 (0.02)**	-0.8 (0.02)***††	-0.8 (0.02)***††	-0.1 (0.03)	-0.7 (0.02)**	-0.9 (0.02)***††	-0.9 (0.02)***††

\* $p < 0.05$ , \*\* $p < 0.001$  vs PBO; † $p < 0.01$ , †† $p < 0.001$  vs ETN. LS: least square; NRS: Numeric Rating Scale; SE: standard error; ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks.